Golodirsen is an antisense oligonucleotide designed as an exon 53-skipping agent for the treatment of Duchenne muscular dystrophy in patients with specific genetic mutations. By binding to the dystrophin… Read more
Golodirsen is an antisense oligonucleotide designed as an exon 53-skipping agent for the treatment of Duchenne muscular dystrophy in patients with specific genetic mutations. By binding to the dystrophin gene transcript, this medication facilitates the skipping of exon 53 to restore functional protein production. In the pharmaceutical industry, high-quality reference standards of Golodirsen, along with its pharmacopeial and non-pharmacopeial impurities and stable isotope labelled compounds, are critical for rigorous analytical testing and method validation. These materials allow laboratories to conduct accurate impurity profiling and stability studies, which are essential for ensuring the consistency and quality of the drug substance. Utilizing these specialized reference materials supports the comprehensive quality control protocols required during the manufacturing and regulatory submission processes for this complex therapeutic agent.